Lantheus announces acquisition of Meilleur Technologies, NAV-4694

Lantheus Holdings announced its acquisition of Meilleur Technologies, Inc., which includes NAV-4694, expanding Lantheus’ Alzheimer’s disease pipeline. Through this acquisition, Lantheus now has the worldwide exclusive rights to ss amyloid PET imaging agent, NAV-4694, also known as F18-flutafuranol. NAV-4694 is currently in Phase 3 development and is also being used in academic and industry investigational therapeutic trials. The acquisition of this asset broadens Lantheus’ Alzheimer’s diagnostic portfolio and complements Lantheus’ next generation F18-labeled PET imaging agent candidate, MK-6240, which targets tau tangles in Alzheimer’s disease. Under the terms of the agreement, Lantheus will provide an upfront payment as well as potential additional development and commercial milestone payments. Additionally, Lantheus will make royalty payments for research revenue and commercial sales. Structured as a stock purchase, the agreement specifies, among other things, that the sellers will also provide transition and clinical development services for a prescribed time following the closing of the transaction.